Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics reports news on its CNS oncology business, which combines precision diagnostics with targeted radiopharmaceutical development for central nervous system cancers. Recurring updates cover REYOBIQ™ (rhenium Re186 obisbemeda), a radiotherapeutic program for indications including leptomeningeal metastases and recurrent glioblastoma, as well as clinical and translational presentations, regulatory designations, manufacturing technology transfer and supply-chain partnerships.
The company’s news also covers the commercial expansion of CNSide®, including payer coverage, Medicare enrollment and reimbursement work for its cerebrospinal fluid assay platform. Corporate updates include leadership appointments, equity inducement grants under Nasdaq rules, financial results, capital actions and listing-compliance matters tied to its Nasdaq-traded common stock.
Plus Therapeutics, a clinical-stage pharmaceutical company, announced that CEO Marc Hedrick will present at the ThinkEquity Conference on October 26, 2022, at 3:00 p.m. ET in New York City. The company is focused on developing innovative radiotherapeutics for rare cancers. Investors can arrange meetings with management during the conference. An archived presentation will be available on their website for 90 days post-event. Plus Therapeutics emphasizes its nanotechnology platform and liposomal encapsulation technology aimed at improving drug delivery for cancer treatment.
Plus Therapeutics, Inc. (PSTV) will report its third quarter 2022 financial results on October 20, 2022, after market close. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and provide corporate updates. The live webcast can be accessed through their investor relations page. The company focuses on developing innovative radiotherapeutics for challenging cancers and utilizes a proprietary nanotechnology platform for drug delivery.
Plus Therapeutics (PSTV) announced that Dr. Andrew Brenner will host a live webinar on October 9, 2022, focusing on a new targeted radiation therapy for leptomeningeal metastases related to breast and lung cancers. This session is part of the Musella Foundation Webinar Series. Leptomeningeal metastases pose significant treatment challenges, and the webinar aims to educate patients about potential therapies. Plus Therapeutics is a clinical-stage pharmaceutical company developing innovative treatments for cancer, leveraging advanced delivery technologies.
Plus Therapeutics (PSTV) announced that its data on Leptomeningeal metastases has been recognized as a “Top Rated Oral Presentation” by EANM. The company will present findings from ongoing clinical trials on its investigational drug, Rhenium-186 NanoLiposome (186RNL), for treating recurrent glioblastoma and leptomeningeal metastases at the 35th Annual Congress of EANM in Barcelona from October 15-19, 2022. The presentations will detail safety and feasibility trials for 186RNL, highlighting its potential in challenging cancer treatments.
Plus Therapeutics (PSTV) has secured a $17.6 million grant from CPRIT to fund the development of its lead investigational treatment, Rhenium-186 NanoLiposome, for leptomeningeal metastases. This funding, expected to be received by October 31, 2022, allows for $3.7 million in Year 1, $6.7 million in Year 2, and $7.2 million in Year 3, extending the company's cash runway through 2025. As of June 30, 2022, Plus Therapeutics reported $18.1 million in cash, bolstering its financial position for ongoing clinical trials and operational activities.
Plus Therapeutics announced Phase 1 results for 186RNL, showing significant safety and survival benefits in patients with recurrent glioblastoma. The trial, presented at ESMO 2022, demonstrated a median overall survival of 22.9 months for patients receiving over 100 Gray of radiation, compared to 5.6 months for lower doses. The company will advance to Phase 2, funded by the NIH, to explore expanded dosing and larger tumors. Observations include no dose-limiting toxicities and enhanced radiation delivery potential, marking a promising step towards treatment advancement.
Plus Therapeutics, Inc. (Nasdaq: PSTV) announced that CEO Marc Hedrick will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 2:00 p.m. ET, in New York City. The presentation will focus on the company’s development of targeted radiotherapeutics for rare cancers. Investors interested in meetings with management should contact the conference coordinator. An archived replay of the presentation will be available on the Plus Therapeutics website for 90 days post-event.
Plus Therapeutics (PSTV) announced the initiation of the ReSPECT-GBM Phase 2 trial, focusing on the Rhenium-186 NanoLiposome (186RNL) for treating recurrent glioblastoma (GBM). The FDA has approved the trial, emphasizing dose exploration and the collection of safety and efficacy data. A future registrational trial will prioritize overall survival as the main endpoint. The trial's principal investigator will provide updates at the ESMO Congress. Plus Therapeutics continues to develop innovative targeted radiotherapeutics for challenging cancers, backed by NIH and CPRIT funding.
Plus Therapeutics, Inc. (PSTV) has announced a significant update following a Type C meeting with the FDA regarding the cGMP production of its investigational radiotherapeutic, 186RNL, aimed at treating recurrent glioblastoma. The FDA supports the company’s CMC practices, aligning with its proposed manufacturing and release strategies. This endorsement is crucial as Plus Therapeutics prepares for ongoing and future ReSPECT™ clinical trials, with cGMP 186RNL expected to be available in the second half of 2022. The company emphasizes that this regulatory clarity mitigates risks of potential delays.
Plus Therapeutics, Inc. (PSTV) has announced an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022 regarding its Phase 1/2a ReSPECT-GBM™ clinical trial. The trial evaluates Rhenium-186 NanoLiposome (186RNL) for treating recurrent glioblastoma. The presentation is scheduled for September 9, 2022, at 14:00 CEST, led by Dr. Andrew J. Brenner. This investigation aims to demonstrate the safety and efficacy of 186RNL in delivering high doses of radiation directly to tumors through Convection Enhanced Delivery (CED).